<DOC>
	<DOCNO>NCT02874846</DOCNO>
	<brief_summary>To evaluate effect Netarsudil Ophthalmic Solution 0.02 % Nocturnal Diurnal Intraocular Pressure .</brief_summary>
	<brief_title>Nocturnal/Diurnal Intraocular Pressure-Lowering Effect Netarsudil Ophthalmic Solution</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . 18 year age old . 2 . Ocular hypertension openangle glaucoma eye . 3 . Unmedicated intraocular pressure &gt; 17 mmHg one eye &lt; 30 mmHg eye . 4 . Corrected visual acuity eye equivalent 20/200 better . 5 . Able willing give sign informed consent follow study instruction . 1 . Glaucoma pseudoexfoliation pigment dispersion component , history angle closure , narrow angle . 2 . Intraocular pressure ≥ 30 mmHg . 3 . Use ocular medication within 30 day . 4 . Known hypersensitivity component test formulation medication use routinely clinical eye examination . 5 . Previous eye surgery ( cataract ) . 6 . Ocular trauma within 6 month . 7 . Clinically significant ocular disease might interfere study . 8 . Central corneal thickness great 620 µm .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>